Boston: LogicFlo AI, the Boston-based startup pioneering intelligent AI agents for regulated industries, has raised $2.7 million in seed funding to revolutionize high-stakes workflows across the life sciences sector.
Led by Lightspeed Venture Partners, the funding round also saw participation from top-tier healthcare and enterprise AI investors.
Founded by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo AI is on a mission to empower life sciences professionals – from medical writers and regulatory strategists to quality and safety teams – with advanced, compliant AI agent support.
Also Read: DeHaat Only Indian AgriTech Startup Featured in 2025 THRIVE Top 50 AgTech Report by SVG Ventures
The company’s AI platform reduces project timelines from weeks to hours while maintaining full regulatory compliance, providing transformational benefits across pharmaceutical, biotech, and medtech companies.
“Unlike traditional automation, LogicFlo AI is built for people – not to replace them, but to amplify them,” said Udith Vaidyanathan, Co-founder and CEO.
“We’re creating an AI-powered workforce that aligns with the nuance, compliance, and complexity of life sciences – putting experts in control of intelligent agents tailored to their workflows.”
LogicFlo AI’s platform replaces fragmented tools with an interactive, auditable system of engagement where agents can follow SOPs, understand organization-specific templates, break work into subtasks, and escalate only when needed.
Also Read: SuperDial Secures USD 15 Million to Expand AI Voice Agents in Healthcare
This ensures safe deployment in regulated environments while delivering dramatic improvements in turnaround time and efficiency.
Real-World Impact Across the Value Chain
Already deployed across global life sciences enterprises – including a Fortune 500 company – LogicFlo’s AI agents are streamlining functions such as:
- Literature-based medical content creation with full citations
- MLR workflow management and compliant commercial material generation
- Regulatory authoring for INDs, CTAs, and safety narratives
- Quality documentation such as SOPs and deviation reports
- Medical information response handling with up to 2000x faster output
LogicFlo AI: Strategic Growth Plans
The newly raised funds will support:
- Expansion of LogicFlo’s AI agent library
- Deeper integrations with life sciences-native systems like Veeva and IQVIA
- Scaling product, engineering, and deployment teams
“LogicFlo AI is redefining how biotech and pharma teams get work done,” said Rohil Bagga, VP Investments at Lightspeed. “Their AI agent platform is purpose-built for high-compliance, high-impact industries, and the founders bring a rare blend of deep domain insight and engineering innovation.”
With the AI-driven transformation of regulated industries gaining momentum, LogicFlo AI is positioned at the forefront of a generational shift in digital health innovation – reshaping how scientific professionals collaborate, execute, and deliver value.
